Tafalgie Therapeutics is growing !

Tafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specialised in the development ... Show more

Participating in the “IPOready 2024” program

Tafalgie Therapeutics is going to participate in the 'IPOready' 2024 program, a pre-IPO program organized by Euronext for the 9th ... Show more

The SATT IMPACT 2022 Prize on the TAFA4 Protein

Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team's work on the TAFA4 Protein . Aziz ... Show more
Visit our contact page